scholarly journals Complex treatment of retinal veins occlusion

2012 ◽  
Vol 93 (6) ◽  
pp. 954-956
Author(s):  
E A Abdulaeva ◽  
A N Amirov ◽  
E P Beriya-Dzhorgzhikiya ◽  
A N Korobitsyn
Keyword(s):  
Visual Acuity ◽  
Retinal Vein Occlusion ◽  
Complex Treatment ◽  
Intravitreal Ranibizumab ◽  
Vein Occlusion ◽  
End Of Treatment ◽  
Visual Acuity Testing ◽  
Spectral Optical Coherence Tomography ◽  
Central Retinal Vein ◽  
Retinal Photocoagulation

Aim. To assess the efficacy of complex treatment of retinal veins occlusion with anti-angiogenic - ranibizumab, and laser retinal photocoagulation. Methods. 36 patients (36 eyes) with occlusion of central retinal vein and its branches were included. Patients with central retinal vein occlusion (n=17) were included in the first group, patients with retinal vein branch occlusion (n=19) were included in the second group. All the patients underwent visual acuity testing, ocular tonometry, ophthalmoscopy, biomicroscopy, spectral optical coherence tomography, intravenous fluorescein angiography at the baseline, 1 and 3 months after treatment. Treatment included intravitreal ranibizumab injection (0.5 mg) and laser retinal photocoagulation 1 month after intravitreal injection. Results. In 94.4% of cases good treatment effect was observed. Visual acuity improved from 0.06±0.03 at baseline to 0.22±0.08 (p 0.05) at the end of treatment in the first group and from 0.31±0.06 to 0.64±0.05 (p 0.05) in the second group. Central retinal thickness reduced from 752.2±98.4 μm to 309.21±45.57 μm (p 0.05) in the first and from 689.12±64.08 μm to 235.37±46.07 μm (p 0.05) in the second group. Conclusion. The results indicate high effectiveness of suggested complex treatment of retinal vein occlusion with anti-angiogenic - ranibizumab and laser retinal photocoagulation.

Prospective Study of Intravitreal Ranibizumab as a Treatment for Decreased Visual Acuity Secondary to Central Retinal Vein Occlusion

2009 ◽  
Vol 147 (2) ◽  
pp. 298-306 ◽  
Author(s):  
Richard F. Spaide ◽  
Louis K. Chang ◽  
James M. Klancnik ◽  
Lawrence A. Yannuzzi ◽  
John Sorenson ◽  
...  
Keyword(s):  
Visual Acuity ◽  
Prospective Study ◽  
Retinal Vein Occlusion ◽  
Central Retinal Vein Occlusion ◽  
Intravitreal Ranibizumab ◽  
Vein Occlusion ◽  
Central Retinal Vein

scholarly journals Relationship between stereopsis and vision-related quality of life following intravitreal ranibizumab injections for central retinal vein occlusion

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Fumiki Okamoto ◽  
Mizuki Tomioka ◽  
Tomoya Murakami ◽  
Shohei Morikawa ◽  
Yoshimi Sugiura ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Visual Acuity ◽  
Retinal Vein Occlusion ◽  
Central Retinal Vein Occlusion ◽  
Post Treatment ◽  
Intravitreal Ranibizumab ◽  
Vein Occlusion ◽  
Related Quality ◽  
Central Retinal Vein

AbstractThe study aimed to evaluate changes in stereopsis and vision-related quality of life (VR-QOL) in patients with central retinal vein occlusion (CRVO) following intravitreal ranibizumab injection (IVR) and investigate the relationship between stereopsis and VR-QOL. This study included 23 treatment-naïve patients with non-ischemic CRVO and 13 age-matched normal controls. Stereopsis, best-corrected visual acuity (BCVA), VR-QOL, and retinal microstructures were examined pre-treatment and 12 months post-treatment. The Titmus Stereo Test (TST) and TNO stereotest (TNO) were used to evaluate stereopsis. VR-QOL was evaluated using the 25-item National Eye Institute Visual Function Questionnaire (VFQ-25). IVR immediately and significantly improved the TST values, TNO values, composite VFQ-25 score, BCVA, and central foveal thickness in patients with CRVO. The 12-month post-treatment TST and TNO values were significantly worse in the CRVO group compared to those in the normal group. At the baseline, the composite VFQ-25 score significantly correlated only with the TST value. Multivariate analysis revealed significant associations between the 12-month post-treatment composite VFQ-25 score and the baseline and 12-month post-treatment TNO values. In conclusion, IVR immediately improved stereopsis in CRVO, albeit below normal levels. Stereopsis (not visual acuity) was associated with pre- and post-treatment VR-QOL in patients with CRVO.

scholarly journals Intravitreal Ranibizumab versus Isovolemic Hemodilution in the Treatment of Macular Edema Secondary to Central Retinal Vein Occlusion: Twelve-Month Results of a Prospective, Randomized, Multicenter Trial

2014 ◽  
Vol 233 (1) ◽  
pp. 8-17 ◽  
Author(s):  
Thomas C. Kreutzer ◽  
Armin Wolf ◽  
Martin Dirisamer ◽  
Rupert W. Strauss ◽  
Paul Foerster ◽  
...  
Keyword(s):  
Visual Acuity ◽  
Macular Edema ◽  
Retinal Vein Occlusion ◽  
Central Retinal Vein Occlusion ◽  
Intravitreal Ranibizumab ◽  
Isovolemic Hemodilution ◽  
Vein Occlusion ◽  
Group I ◽  
Group Ii ◽  
Central Retinal Vein

Purpose: This is a prospective, randomized, multicenter, investigator-initiated trial to evaluate the 12-month effectiveness of isovolemic hemodilution (IH) with prompt versus deferred intravitreal injections (IVI) of ranibizumab 0.5 mg for the treatment of macular edema secondary to early central retinal vein occlusion (CRVO). Methods: Eyes with macular edema due to CRVO having occurred not more than 8 weeks previously received either monthly ranibizumab IVI in combination with IH (group I, n = 28) or IH alone (group II, n = 30). From month 2 to 12, the patients in both groups could be treated with monthly intravitreal ranibizumab. The main outcome variables were gain of visual acuity and the course of central retinal thickness as measured with optical coherence tomography. Results: At 12 months, eyes in group I on average gained +28.1 (±19.3) letters compared to +25.2 (±20.9) letters in group II (p = 0.326). This result was achieved with significantly fewer injections in group II. Additionally, 30% of the eyes in group II did not need ranibizumab IVI during the 12 months of the trial. Conclusion: Ranibizumab IVI in addition to IH proved to be highly effective in increasing visual acuity and reducing macular edema secondary to CRVO. Initial IH in early CRVO may be a first treatment option in patients anxious about IVI.

scholarly journals Laser Treatment in Central Retinal Vein Occlusion and Macular Edema

2019 ◽  
pp. 50-53
Keyword(s):  
Visual Acuity ◽  
Macular Edema ◽  
Retinal Vein Occlusion ◽  
Central Retinal Vein Occlusion ◽  
Vein Occlusion ◽  
Pan Retinal Photocoagulation ◽  
Laser Treatments ◽  
Visual Acuity Loss ◽  
Central Retinal Vein ◽  
Retinal Photocoagulation

Central retinal vein occlusion can result in severe visual acuity loss that is a common retinal vascular disorder. There are two distinct laser treatments: Grid and scatter pan-retinal photocoagulation. Grid laser aims to reduce macular edema and improve visual acuity. The aim of scattering pan-retinal photocoagulation to reduce VEGF burden by ablating peripheral ischemic retina and prevent the development of neovascularization in the retina, iris, and angle or to provide regression if developed. Laser photocoagulation is currently performed in combination with intravitreal anti-VEGF and intravitreal steroid treatments, but not alone in retinal vein occlusion.

scholarly journals Relationship Between Stereopsis and Vision-Related Quality of Life Following Intravitreal Ranibizumab Injections for Central Retinal Vein Occlusion

2021 ◽  
Author(s):  
Fumiki Okamoto ◽  
Mizuki Tomioka ◽  
Tomoya Murakami ◽  
Shohei Morikawa ◽  
Yoshimi Sugiura ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Visual Acuity ◽  
Retinal Vein Occlusion ◽  
Central Retinal Vein Occlusion ◽  
Post Treatment ◽  
Intravitreal Ranibizumab ◽  
Vein Occlusion ◽  
Related Quality ◽  
Central Retinal Vein

Abstract The study aimed to evaluate changes in stereopsis and vision-related quality of life (VR-QOL) in patients with central retinal vein occlusion (CRVO) following intravitreal ranibizumab injection (IVR) and investigate the relationship between stereopsis and VR-QOL. This study included 23 treatment-naïve patients with CRVO and 13 age-matched normal controls. Stereopsis, best-corrected visual acuity (BCVA), VR-QOL, and retinal microstructures were examined pre-treatment and 12 months post-treatment. The Titmus Stereo Test (TST) and TNO stereotest (TNO) were used to evaluate stereopsis. VR-QOL was evaluated using the 25-item National Eye Institute Visual Function Questionnaire (VFQ-25). IVR immediately and significantly improved the TST values, TNO values, composite VFQ-25 score, BCVA, and central foveal thickness in patients with CRVO. The 12-month post-treatment TST and TNO values were significantly worse in the CRVO group compared to those in the normal group. The baseline composite VFQ-25 score significantly correlated with the TST value. Multivariate analysis revealed significant associations between the 12-month post-treatment composite VFQ-25 score and the baseline and 12-month post-treatment TNO values. In conclusion, IVR immediately improved stereopsis in CRVO, albeit below normal levels. Stereopsis (not visual acuity) was associated with pre- and post-treatment VR-QOL in patients with CRVO.

scholarly journals Efficacy and Safety of an Aflibercept Treat-and-Extend Regimen in Treatment-Naïve Patients with Macular Oedema Secondary to Central Retinal Vein Occlusion (CRVO): A Prospective 12-Month, Single-Arm, Multicentre Trial

2018 ◽  
Vol 2018 ◽  
pp. 1-7
Author(s):  
Jose Garcia-Arumi ◽  
Francisco Gómez-Ulla ◽  
Navea Amparo ◽  
Enrique Cervera ◽  
Alex Fonollosa ◽  
...  
Keyword(s):  
Visual Acuity ◽  
Retinal Vein Occlusion ◽  
Central Retinal Vein Occlusion ◽  
Macular Oedema ◽  
Efficacy And Safety ◽  
Foveal Thickness ◽  
Treat And Extend ◽  
Vein Occlusion ◽  
Treatment Naïve ◽  
Central Retinal Vein

Objectives. To evaluate efficacy and safety of an aflibercept treat-and-extend (TAE) regimen in patients with macular oedema (MO) secondary to central retinal vein occlusion (CRVO). Design, Setting, and Patients. Phase IV, prospective, open-label, single-arm trial in 11 Spanish hospitals. Treatment-naïve patients with <6 month diagnosis of MO secondary to CRVO and best-corrected visual acuity (BCVA) of 73-24 ETDRS letters were included between 23 January 2015 and 17 March 2016. Intervention. Intravitreal aflibercept 2 mg monthly (3 months) followed by proactive individualized dosing. Main Outcomes. Mean change in BCVA after 12 months. Results. 24 eyes (24 patients) were included; mean (SD) age: 62.8 (15.0) years; 54.2% male; median (IQR) time since diagnosis: 7.6 (3.0, 15.2) days. Mean BCVA scores significantly improved between baseline (56.0 (16.5)) and Month 12 (74.1 (17.6)); mean (95% CI) change: 14.8 (8.2, 21.4); P=0.0001. Twelve (50.0%) patients gained ≥15 ETDRS letters. Foveal thickness improved between baseline (mean: 569.4 (216.8) µm) and Month 12 (mean 257.4 (48.4) µm); P<0.0001. At Month 12, 8.3% patients had MO. The mean (SD) number of injections: 8.3 (3.0). No treatment-related AEs were reported. Five (20.8%) patients experienced ocular AEs. Two nonocular serious AEs were reported. Conclusions. An aflibercept TAE regimen improves visual acuity in patients with MO secondary to CRVO over 12 months with good tolerability.

Sign in / Sign up

Export Citation Format

Share Document